Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.



PRESS ROOM
07/13/10 Protalix BioTherapeutics Announces French ATU Granted for taliglucerase alfa for the Treatment of Gaucher Disease
07/12/10 Protalix BioTherapeutics Receives PDUFA Date for taliglucerase alfa
06/08/10 Protalix BioTherapeutics Completes Phase I Clinical Trial for PRX-105
04/27/10 Protalix Submits Validation Data on Manufacturing Process to FDA
PROTALIX BIOTHERAPEUTICS

2 Snunit St., Science Park,
POB 455, Carmiel 20100, Israel.

T:   +972-4-9028100
F:   +972-4-988-9489
E:   
      
© 2007 Protalix Biotherapeutics. All Rights Reserved.